Price T Rowe Associates Inc Repligen Corp Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Repligen Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 7,136,054 shares of RGEN stock, worth $1.04 Billion. This represents 0.12% of its overall portfolio holdings.
Number of Shares
7,136,054
Previous 6,392,239
11.64%
Holding current value
$1.04 Billion
Previous $951 Million
7.98%
% of portfolio
0.12%
Previous 0.11%
Shares
17 transactions
Others Institutions Holding RGEN
# of Institutions
481Shares Held
56.3MCall Options Held
251KPut Options Held
458K-
Black Rock Inc. New York, NY7.57MShares$1.1 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$741 Million0.01% of portfolio
-
State Street Corp Boston, MA1.69MShares$246 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.54MShares$224 Million1.48% of portfolio
-
Sands Capital Management, LLC Arlington, VA1.36MShares$198 Million0.62% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.06B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....